Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongying Yang

Showing results (181-190 of 192) with videos related to

Pageof 20
Sort By:
Cell Reports|June 9, 2021
Human amyotrophic lateral sclerosis excitability phenotype screen: Target discovery and validationXuan Huang, Kasper C D Roet, Liying Zhang, et al.
Hypertension (Dallas, Tex. : 1979)|May 12, 2020
Folic Acid Supplement Use and Increased Risk of Gestational HypertensionQian Li, Shangzhi Xu, Xi Chen, et al.
Experimental Hematology & Oncology|November 22, 2025
Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumorsRongrui Liu, Rongbo Lin, Ning Li, et al.
JAMA Oncology|July 13, 2023
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical TrialNing Li, Jianqing Zhu, Rutie Yin, et al.
Journal of Ovarian Research|December 17, 2025
A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC)Li Wang, Lingling Xie, Qingshui Li, et al.
Nature|November 30, 2007
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetesJill C Milne, Philip D Lambert, Simon Schenk, et al.
BMC Cancer|December 5, 2022
Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trialYingjie Hu, Yingyan Han, Yuanming Shen, et al.
Nature Communications|December 21, 2025
Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trialXiaohua Wu, Jing Wang, Danbo Wang, et al.
Eclinicalmedicine|May 15, 2024
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trialXiaohua Wu, Jianqing Zhu, Rutie Yin, et al.
CA: a Cancer Journal for Clinicians|November 25, 2025
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trialLingying Wu, Jing Wang, Qingshui Li, et al.
Pageof 20

Showing results (181-190 of 192) with videos related to

Sort By:
Pageof 20
Cell Reports|June 9, 2021
Human amyotrophic lateral sclerosis excitability phenotype screen: Target discovery and validationXuan Huang, Kasper C D Roet, Liying Zhang, et al.
Hypertension (Dallas, Tex. : 1979)|May 12, 2020
Folic Acid Supplement Use and Increased Risk of Gestational HypertensionQian Li, Shangzhi Xu, Xi Chen, et al.
Experimental Hematology & Oncology|November 22, 2025
Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumorsRongrui Liu, Rongbo Lin, Ning Li, et al.
JAMA Oncology|July 13, 2023
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical TrialNing Li, Jianqing Zhu, Rutie Yin, et al.
Journal of Ovarian Research|December 17, 2025
A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC)Li Wang, Lingling Xie, Qingshui Li, et al.
Nature|November 30, 2007
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetesJill C Milne, Philip D Lambert, Simon Schenk, et al.
BMC Cancer|December 5, 2022
Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trialYingjie Hu, Yingyan Han, Yuanming Shen, et al.
Nature Communications|December 21, 2025
Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trialXiaohua Wu, Jing Wang, Danbo Wang, et al.
Eclinicalmedicine|May 15, 2024
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trialXiaohua Wu, Jianqing Zhu, Rutie Yin, et al.
CA: a Cancer Journal for Clinicians|November 25, 2025
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trialLingying Wu, Jing Wang, Qingshui Li, et al.
Pageof 20